AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03245879 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Program 1
Description: Program 1 hospitals received a basic curriculum and tools for implementation of basic antibiotic stewardship interventions. Hospitals required an indication for every antibiotic order. A daily email was sent to a designated email account when a patient had been on an antibiotic for >48 hours. Curriculum included implementing antibiotic time-outs, IV to PO conversion, indications, evaluating for bug-drug mismatches, and recommendations on when to call the Infectious Diseases (ID) hotline. A daily antibiotic stewardship check list was created. All materials were provided to all pharmacists and remained on-site. Clinicians had access to an ID telephone hotline to answer clinical questions. Pharmacy directors and hospital leadership were provided a monthly, hospital-specific, antibiotic use dashboard. All pharmacy directors and staff received a monthly newsletter.
Study NCT03245879 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Program 2
Description: Program 2 hospitals received all the interventions of Program 1. In addition, Program 2 hospitals received more intense antibiotic stewardship education. Educational topics included audit and feedback, antibiotic de-escalation, the need for antibiotics targeting anaerobic bacteria, antibiotic allergy verification, and antibiotic restrictions. Pharmacists in Program 2 hospitals reviewed patients on vancomycin, piperacillin/tazobactam, imipenem, meropenem, and cefepime. For patients receiving one of these antibiotics, pharmacists reviewed the patients' microbiology data to identify opportunities for antibiotic de-escalation, IV to PO conversion, bug-drug mismatches, and/or indications for calling the ID hotline. Program 2 hospitals also restricted daptomycin, linezolid, imipenem, meropenem, ceftaroline, tigecycline, and all mold active antifungals. In Program 2 hospitals, the local pharmacy staff pre-authorized restricted antibiotics based on defined criteria.
Study NCT03245879 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Program 3
Description: Program 3 hospitals received all the interventions of Program 1 and Program 2. In addition, pharmacists in program 3 hospitals reviewed an expanded list of antibiotics for audit and feedback. These antibiotics included: Vancomycin, piperacillin/tazobactam, imipenem, meropenem, cefepime, ertapenem, aminoglycosides, ceftriaxone, and fluoroquinolones. Program 3 hospitals implemented the same antibiotic restrictions as Program 2 but ID pharmacists controlled pre-authorization of restricted antibiotics. In addition, an ID physician reviewed pre-specified positive cultures (e.g. all positive blood cultures, cultures with highly resistant Enterobacteraciae) and contacted providers with recommendations as needed. ID physician review occurred Monday through Friday and alerts were batched daily at 6am.
Study NCT01743430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telerehabilitation
Description: telerehabilitation for 4 weeks, 2 sessions per week and 30 to 50 minutes per session
Study NCT05410990 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: eosinophil and other hematological parameters
Study NCT00596544 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: will be offered referral to the Sexual Health Clinic (SHC) at MSKCC for evaluation and possible treatment. The effectiveness and compliance of the intervention offered at the SHC will be assessed at approximately 3, 6 and 12 months using the FSFI, SAQ, CES-D, MSC and IES. At each evaluation they will complete a Health Surveillance Form (HSF). They will have completed the study at 12 months after entering the study or at the time they have evidence of recurrent disease requiring treatment
Study NCT00596544 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: Those women who have a FSFI score > 26 will be reassessed at approximately 3, 6 and 12 months. They will complete the FSFI, SAQ, CES-D, IES, MSC and HSF at each assessment. They will be followed out until 12 months after entering the study or until they have evidence of recurrent disease.
Study NCT03431610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB414 2%
Description: Twice daily
Study NCT03431610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB414 6%
Description: Twice daily
Study NCT01606878 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01606878 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01606878 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01606878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV
Study NCT03407482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0853
Description: Participants received GDC-0853 at a dose of 200mg, as per the dosing schedule described above.
Study NCT03431610 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Placebo comparator
Study NCT03052036 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Coronary Angiography
Description: Coronary angiography to determine location of blocked or narrowed arteries.
Study NCT03052036 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Coronary revascularisation
Description: PCI or CABG will be performed following coronary angiography at the discretion of the treating cardiologist.
Study NCT03052036 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Optimal Medical Therapy
Description: Patients to receive conservative treatment in the form of guideline recommended secondary prevention therapy including antiplatelet therapy, statins, ACE Inhibitors and beta blockers.
Study NCT04143048 — intervention group
Intervention type: OTHER
Intervention: DNA extraction of tumer tissue samples and high-throughput sequencing of small panels
Description: DNA extraction of stromal tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed
Study NCT04143048 — intervention group
Intervention type: OTHER
Intervention: DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels
Description: DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood cfDNA and tissue gDNA for the gene detection of gastrointestinal stromal tumor
Study NCT04143048 — intervention group
Intervention type: OTHER
Intervention: DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels
Description: DNA extraction and small panel sequencing were conducted for each patient sample. Based on the indicator results of the previous mutant spectrum for each stage of gastrointestinal stromal tumor, the clinical stage classification of patients and the benign and malignant nodules were determined by the mutant spectrum, and compared with the real clinical data of patients
Study NCT00627978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: ixabepilone 40 mg/m2 Q3w over 3 hours
Study NCT01069939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 20mg, capsule, 72 weeks
Study NCT01069939 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, capsule, 72 weeks
Study NCT01890993 — intervention group
Intervention type: DRUG
Intervention: liraglutide
Description: Anonymised patient level data will be collected by the patients' own general practitioner and electronic case report form (eCRF) will be used to capture the data.
Study NCT04359212 — intervention group
Intervention type: DRUG
Intervention: thromboprophylaxis with low-molecular-weight heparin or fondaparinux
Description: thromboprophylaxis with low-molecular-weight heparin or fondaparinux
Study NCT02969278 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 18FDG-PET/TC
Description: Nuclear medicine exam (18FDG-PET/TC) to assess the status of the regional groin and pelvic lymphnodes
Study NCT02969278 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy
Description: Intradermal injection of 0.2 ml 37-148 MBq of radiocolloid and a blue dye near the tumor to locate the position of the sentinel lymph node. Intraoperatively, sentinel node localization is guided by a gamma probe and by the eyes of the surgeon who detects the lymph nodes that are stained with the blue dye.
Study NCT04571632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab 5 MG/ML
Description: Ipilimumab (50mg/10mL solution) will be administered by intratumoral injection at a maximum total dose of 10 mg (= 2 ml of a 50mg/10ml solution) on day 1 followed by a subsequent intratumoral injections on day 15, 29, 43, 57 and 71.~Total administered dose of ipilimumab (50mg/10mL solution) will be up to 2.0 mL per treatment. Injected volume per lesion will range from 0.05 mL for lesions \< 0,5 cm to 2.0 mL for lesions > 5 cm in longest diameter.~Injection of all lesions in individual patients will not be required. Determination of ipilimumab (50mg/10mL solution) injection volume based on lesion size
Study NCT04516876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Camp-based bimanual intensive training(BIT)
Description: The day-camp BIT model will be delivered in a group-based design. In day-camp model, each child is assigned to a trained therapist to maintain at least a 1:1 to 1:2 ratios of therapy and child. The therapist will monitor and modify the activities to fit each individual's ability and need to make sure the intervention quality is equivalence to the individualized treatment method. The chosen tasks of each intervention session have to be considering the child's preference, age-appropriated, and at the right level of difficulty. Target movements are embedded in the functional activities, whereby the environment is manipulated to vary task requirement and the difficulty is graded to match the child's capacity.
Study NCT03626675 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: phaco- trabeculectomy
Description: combined phaco-trabeculectomy surgery
Study NCT01067300 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transplantation of unrelated cord blood unit(s)
Description: Myeloablative conditioning regimen includes, according to the patient age, either total body irradiation, fludarabine and cyclophosphamide with a GvHD prophylaxis based on cyclosporine A and mycophenolate, or the association busulfan, cyclophosphamide and anti-thymocyte globulin with GvHD prophylaxis being cyclosporine A and steroids.
Study NCT04607031 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of serum ST2 concentrations in serum of patients with acute, ischemic stroke
Description: 7 measurements of serum ST2 concentrations from day 0 to day 6, modified Rankin scale before, 6th and 90th day, NIHSS from day 0 to day 6 and 90, TOAST and OCSP classifications
Study NCT00080106 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MRK Ad5 HIV-1 gag vaccine
Description: MRK Ad5 HIV-1 gag vaccine injected into the upper arm muscle.
Study NCT00080106 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vaccine placebo
Description: MRK Ad5 HIV-1 gag placebo vaccine injected into the upper arm muscle.
Study NCT03846375 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: DBT is a well-established treatment for recurrent self-harm and suicidal thoughts. The program is principle-based, but the skills training follow a manualized curriculum.
Study NCT03846375 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pre-intervention testing
Description: Pre-intervention testing for baseline measures.
Study NCT03846375 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-intervention testing
Description: Pre-intervention testing for baseline measures.
Study NCT02701491 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginger
Description: ginger
Study NCT02701491 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02512562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AL-335
Description: AL-335 is a prodrug being developed as an orally administered anti-HCV therapeutic.
Study NCT02512562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACH-3102
Description: ACH-3102 is an NS5A inhibitor being developed as an orally administered anti-HCV therapeutic.
Study NCT02512562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simeprevir
Description: Simeprevir is an orally active, small molecule inhibitor of the NS3/4A protease of HCV and indicated for the treatment of chronic HCV infection as a component of a combination antiviral treatment regimen.
Study NCT01249196 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: SK-PC-B70M
Description: for dosage
Study NCT01249196 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SK-PC-B70M
Description: for dosage
Study NCT01249196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SK-PC-B70M
Description: for dosage
Study NCT02679105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALK Alutard birch or 5-grasses
Description: 3 injections with 4-5 weeks interval.
Study NCT02679105 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALK diluent
Description: 0,3% human albumin
Study NCT03868371 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High phosphorous containing meal
Description: A meal with a high phosphorous content
Study NCT03868371 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low phosphorous containing meal
Description: A meal with a low phosphorous content
Study NCT03514797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleaching Agents
Description: In-office tooth bleaching with 35% hydrogen peroxide in a single application of 45 minutes.
Study NCT03514797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bleaching Agents
Description: At-home tooth bleaching with 10% carbamide peroxide for 1 hour per day.
Study NCT03514797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleaching Agents
Description: At-home tooth bleaching with 10% carbamide peroxide for 1 hour per day.
Study NCT01560702 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Epinephrine
Description: 10-30 cc of 1/10000 diluted epinephrine will be injected at edges of an actively bleeding ulcer.
Study NCT01560702 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood
Description: 5-20 cc autologous blood immediately withdrawn from the patient will be injected at edges of the actively bleeding ulcer.
Study NCT03120793 — intervention group
Intervention type: DEVICE
Intervention: Esophageal balloon catheter
Description: Measurements obtained from mechanically ventilated patients with ARDS in the supine, upright and prone positions
Study NCT04249778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Participants will receive 10 mg/day of dapagliflozin, beginning at hospital discharge, for 26 weeks.
Study NCT04249778 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a placebo to match 10 mg/day of dapagliflozin, beginning at hospital discharge, for 26 weeks.
Study NCT03233217 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIV-HD by IM
Description: IM, injected into the upper arm (deltoid area)
Study NCT04571632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab 100 MG in 4 ML Injection
Description: The first administration of pembrolizumab 200 mg (100 mg/4mL solution) by the intravenous route during 30 minutes will be administered on day 1. The second administrations of pembrolizumab 200 mg will be administered by a 30 minutes intravenous infusion on day 21, and thereafter every 21 days (or up to ± 3 days before or after the scheduled date if necessary) days.
Study NCT04571632 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC
Description: CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC will be administered by intratumoral injection in the lesions that were injected by avelumab en ipilimumab on day 1 (approximately 24 hours after intratumoral injection of avelumab en ipilimumab).~The total administered CD1c (BDCA-1)+/ CD141 (BDCA-3)+ myDC volume will be up to 4.0 mL per intratumoral treatment session. Injected volume per lesion (skin-, soft tissue or lymph-node metastases) will range from 0.1 mL for lesions \< 0,5 cm to 4.0 mL for lesions > 5 cm in longest diameter. Injection of all lesions in an individual patient will not be required.~The determination of CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC injection volume is based on lesion size.~When lesions are clustered together, they are injected as a single lesion according to the table for determination of CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC injection volume based on lesion size.
Study NCT03233217 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: QIV-SD by SC
Description: SC, injected into the upper arm (posterior region)
Study NCT03233217 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIV-HD by SC
Description: SC, injection into the upper arm (posterior region)
Study NCT01590875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine arm
Description: In the adenosine arm, 25 patients will be randomized to received 2 doses of adenosine 12 mg IV, 5 minutes apart after pulmonary vein isolation. During this time, will monitor for pulmonary vein reconnection, second dose of adenosine will be given only if no reconnection after initial dose. In the observation arm, 25 patients will be randomized to 10 minute period of observation for pulmonary vein reconnection after documentation of pulmonary vein isolation.
Study NCT00886457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and Pegylated Interferon-Alfa 2B
Description: Patients will receive decitabine 3.7 mg/m2/day i.v. over 1 hour daily in 10 doses over 2 weeks elapsed time (Monday-Friday) every 28 days plus fixed dose of PEG-Intron (0, 0.5, 1.5, 3 or 6 mcg/kg PEG-Intron) weekly by subcutaneous injection in 28-day cycles .
Study NCT03602781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo at a dose setting of 75 mcg/kg IBW/hr
Study NCT03602781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: iNO
Description: iNO at a dose setting of 75 mcg/kg IBW/hr
Study NCT03602781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iNO
Description: iNO at a dose setting of 75 mcg/kg IBW/hr
Study NCT03535415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Growth Hormone Injection (rhGH)
Description: rhGH 0.05mg/kg/d by subcutaneous injection
Study NCT04113993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bazedoxifene Acetate
Description: Oral Bazedoxifene dosed at 40 mg daily for 12 weeks
Study NCT04113993 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identically packaged placebo capsule daily
Study NCT02015156 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05280014
Description: Concentrate for solution for infusion, sterile vial 150 mg, single-dose 6 mg/kg administered as 90-minute infusion on Day 1
Study NCT02015156 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin®
Description: Concentrate for solution for infusion, sterile vial 440 mg, single-dose 6 mg/kg administered as 90-minute infusion on Day 1
Study NCT01197066 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Certolizumab Pegol
Description: Certolizumab Pegol 200mg
Study NCT02013427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Take one 500mg naproxen capsule twice a day.
Study NCT02013427 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take one placebo capsule twice a day.
Study NCT02013427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Take one 20mg omeprazole capsule twice a day.
Study NCT03100747 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilamellar 3 mm
Description: Trichiasis surgery using the bilamellar tarsal rotation procedure with incision 3 mm from the eyelid margin
Study NCT03100747 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilamellar 5 mm
Description: Trichiasis surgery using the bilamellar tarsal rotation procedure with incision 5 mm from the eyelid margin
Study NCT03100747 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabut 3 mm
Description: Trichiasis surgery using Trabut procedure with incision 3 mm from the eyelid margin
Study NCT03906994 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video game Mario Kart Wii
Description: Subjects will place a patch over the better-seeing eye and play the video game Mario Kart Wii for a total of 40 hours over a 1 month perior
Study NCT00165698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: menatetranone
Description: 15 mg three times a day orally for 12 months
Study NCT00165698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alfacalcidol
Description: 0.25 μg twice a day orally for 12 months